ReviewInternational journal of preventive medicine2024
Economic Burden of Hepatitis B at Different Stages of the Disease: A Systematic Review Study.
Review in International journal of preventive medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Encountering the Other in the Digital Sphere: Emmanuel Levinas' "Ethics of the Face" and the Implications for Virtual Healthcare Ethics in Contemporary Society.Journal of religion and health · 2026Article
- Mediation Analysis of the Relationship Between Health Literacy and the French General Population's Opinions on Hepatitis B Vaccination: Representative Cross-Sectional Survey of the SLAVACO Project.JMIR public health and surveillance · 2026Article
- Impact of the COVID-19 Pandemic on Vaccine-Preventable Diseases in Mexico: A Time Series Analysis (2014-2024).Epidemiologia (Basel, Switzerland) · 2026Article
- Young adult immunization initiative (YUVA/YAII): A policy framework for India's life-course vaccination strategy.The Indian journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Viral hepatitis is the most prevalent liver disease in the world. This disease imposes a great economic burden on families and the health system. This study was conducted to investigate the economic burden of hepatitis B at different ages of the disease using a systematic review method. Methods: Using the systematic review method, the researcher extracted articles related to the economic burden of hepatitis B at different stages of the disease using domestic and international databases including SID, MEDLINE/PubMed, Embase, Web of Science, NHS Economic Evaluation Database (EED), EconLit, and Google Scholar before April 2020 and used the PICOTS framework to select the inclusion criteria. Quality assessment of methodology of the studies was evaluated using Drummond's checklist. Results: After searching for articles based on inclusion and exclusion criteria, 18 articles were included in the final analysis. The findings showed that the highest mean direct medical costs were $ 2748 for chronic hepatitis B, $ 18903 for compensated cirrhosis, $35668 for decompensated cirrhosis, and $93228 for liver cancer. In all of the studies, the highest mean direct medical costs were those of liver transplantation ($ 355000). Conclusions: The treatment costs of diseases related to chronic hepatitis B increase significantly at different stages the disease progression. Although vaccination actions can reduce the disease, we require more investment in the health system infrastructure to provide patients' access to hepatitis drugs and reduce their direct payments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.